Oslo, March 28 2025. Navamedic ASA (OSE ticker "NAVA") has received a letter
from the Norwegian Financial Supervisory Authority (the "NFSA") regarding the
accounting of Navamedic's loans to Observe Medical ASA in relation to the
Company's annual financial statements for 2023.

The NFSA's assessment is that there are misstatements in the annual financial
statements for 2023 and in the interim financial statements for 2024 related to
the Company's accounting of the two loans Navamedic has to Observe Medical ASA,
interest on those loans and the information provided in the notes to the
accounts.

The Company will assess the information received and implement any required
corrections of the accounts.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:
kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:
lars.hjarrand@navamedic.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Lars Hjarrand, CFO of the
Company, on 28 March 2025 at 14:24 hours CET on behalf of the Company.

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to
empower people to live healthier and more fulfilling lives. What sets us apart
is our deep-rooted commitment to understanding the needs and requirements of the
countries where we are present. Our local insight and competence enable us to
understand the specific needs of each country where we operate and ultimately to
gain market access. This makes us a preferred partner for international
companies expanding their footprint across the Nordics and Benelux regions,
through either in-licensing or out-licensing. Navamedic has been listed on the
Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo,
Norway. For more information, please visit Navamedic.com.